BEAM

AI Memo

Beam Therapeutics

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Risto-cel data and potential BLA submission • 2026-12-31

Base target: $29 / p=50% prob

Biggest risk

BEAM-302's interim biomarkers are not proof of clinical benefit or an accepted accelerated-approval package. Safety, enrollment, regulatory requirements, risto-cel filing timing and continued R&D spending could materially weaken the thesis.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

The September BEAM-302 biomarker update and pivotal-cohort start support a cautiously positive development thesis. Risto-cel and BEAM-301 offer distinct 2026 milestones, while Beam reported $1.153 billion of cash, equivalents and marketable securities at June 30, 2026 [#IR-2026-09-08][#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

$29

p=50%

Bull target

$43

p=25%

Bear target

$13

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BEAM-302 pivotal-cohort progress
The September BEAM-302 biomarker update and pivotal-cohort start support a cautiously positive development thesis.
Risto-cel and BEAM-301 offer distinct 2026 milestones, while Beam reported $1.153 billion of cash, equivalents and marketable securities at June 30, 2026 [#IR-2026-09-08][#SEC-8K-2026-08-04].

BearKey bullets

Beam reported a $122.7 million second-quarter net loss; its stated runway into mid-2029 assumes, among other things, an expected additional $200 million draw under its Sixth Street facility [#SEC-8K-2026-08-04].
Beam's September trade-secret lawsuit creates legal cost and intellectual-property uncertainty.
The claims are allegations, not established misconduct or evidence of clinical-program performance.

WatchKey bullets

Risto-cel data and potential BLA submission

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $29 (p=50%)

Target spread vs base: +48% / -55%

Scenario probabilities

Bull Target: $43 (p=25%)Base Target: $29 (p=50%)Bear Target: $13 (p=25%)

Commentary

Primary clinical evidence remains constructive, but BEAM-302's pivotal outcome is unresolved. The $24.39 October 1 anchor is about 0.5% above the prior baseline's $24.27 September 25 anchor; the packet does not establish why shares moved. Recent litigation coverage adds a risk to monitor, not a proven operating setback. Analyst revisions, options positioning, short interest, employee sentiment and sufficiently covered social sentiment were unavailable; zero fields denote missing measurements, not neutral readings.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BEAM-302 pivotal-cohort progress

Scenarios

Bull Target (Scenario probability)

$43 / p=25% prob

Base Target (Scenario probability)

$29 / p=50% prob

Bear Target (Scenario probability)

$13 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Risto-cel data and potential BLA submission
Beam says dosing is complete for adult and adolescent patients in the BEACON sickle-cell trial. It expects updated data by year-end 2026 and a U.S. BLA submission as early as year-end; timing and regulatory sufficiency remain uncertain [#8-K-2026-08-04][#SEC-8K-2026-08-04]. Source: https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm
Prob 60.00% • Move 15.00% • Priced-in 45.00%
EVENT2026-12-31
Initial BEAM-301 clinical data
Beam expects initial 2026 clinical data from its Phase 1/2 BEAM-301 trial in glycogen storage disease type Ia. An early human safety and activity signal could broaden confidence in its liver-targeted platform, but a small dataset may be inconclusive [#SEC-8K-2026-08-04]. Source: https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm
Prob 55.00% • Move 10.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

BEAM-302 pivotal-cohort progress
2027-06-30
Beam reported that BEAM-302 raised mean circulating AAT to 14.4 µM from 5.0 µM at baseline in the Part A 60 mg cohort and that dosing is underway in an approximately 50-patient pivotal cohort. Enrollment, safety and 12-month biomarker results remain the tests of its proposed accelerated-approval path; FDA agreement is not assured [#IR-2026-09-08]. Source: https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-presents-updated-clinical-data-phase-12-trial
Prob 65% • Move 24% • Priced-in 50%

Risks

Beam reported a $122.7 million second-quarter net loss; its stated runway into mid-2029 assumes, among other things, an expected additional $200 million draw under its Sixth Street facility [#SEC-8K-2026-08-04].
Beam's September trade-secret lawsuit creates legal cost and intellectual-property uncertainty. The claims are allegations, not established misconduct or evidence of clinical-program performance. Docket: https://dockets.justia.com/docket/massachusetts/madce/1%3A2026cv14414/306818
Clinical enrollment, manufacturing, regulatory review or data requirements could delay BEAM-302 or the anticipated risto-cel BLA [#SEC-8K-2026-08-04].
The BEAM-302 update included infusion-related reactions and one transient Grade 3 ALT/AST elevation; the proposed biomarker-based accelerated-approval path remains subject to FDA agreement [#IR-2026-09-08].

Peers

Symbol	Summary
AMGN	Amgen is only a broad biotechnology commercialization benchmark; its scale and marketed portfolio make direct valuation comparisons with clinical-stage Beam unreliable.
PRME	Prime Medicine is a relevant but imperfect gene-editing and AATD-development comparator. Its editing approach and programs differ, and its August release's account of an arbitration outcome involving Beam does not establish BEAM-302 performance [#PR-EARNINGS-2026-08-06].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

AMGN

Amgen is only a broad biotechnology commercialization benchmark; its scale and marketed portfolio make direct valuation comparisons with clinical-stage Beam unreliable.

PRME

Prime Medicine is a relevant but imperfect gene-editing and AATD-development comparator. Its editing approach and programs differ, and its August release's account of an arbitration outcome involving Beam does not establish BEAM-302 performance [#PR-EARNINGS-2026-08-06].